Gilead to acquire Tubulis for up to 5 billion dollars

Gilead will acquire Germany-based Tubulis for up to 5 billion dollars. The deal adds a class of experimental cancer drugs to the firm's oncology pipeline.

Xurve View
Insights:

In a significant expansion of its oncology research, GILEAD SCIENCES INC announced on Tuesday that it will acquire Germany-based Tubulis GmbH for a deal valued at up to $5 billion. This strategic move is expected to bolster the United States drugmaker's pipeline with a highly sought-after class of experimental cancer treatments.

An office building of Gilead Sciences, Inc. is pictured in Foster City, California, during May 2018. REUTERS/Stephen Lam/File Photo